Understanding Higher Risk MDS and Transtion to AML

#HEMEPATH Navigating Change and Integrating WHO 5th/ ICC Classification Systems in the diagnosis …Подробнее

Understanding QoL (Quality of life) in High-Risk MDS & AMLПодробнее

MDS - AML - 2020 Spring Virtual Conference: When MDS becomes AML - for High-Risk MDS PatientsПодробнее

Understanding AMLПодробнее

Higher-risk MDS and newly diagnosed AML: What are the latest developments from EHA 2022?Подробнее

Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and managementПодробнее

What Are My Options with High Risk MDS AMLПодробнее

From MDS to AML: What Every Patient Needs to Know 11/28/17Подробнее

Venetoclax in Higher-Risk MDS/AMLПодробнее

2022 Scientific Symposium Highlights for Patients: Treatments for MDS and Secondary AMLПодробнее

Advances in Treating High Risk MDS and AMLПодробнее

High-Risk MDS/AML: Genomic-Driven Approaches from ASH19 - Eytan Stein, MDПодробнее

Treatments for MDS and Secondary AML - Part 2, High-RiskПодробнее

Managing Higher Risk MDL and AMLПодробнее

Uma Borate: Evaluating MBG453 in High-Risk MDS and AMLПодробнее

High Risk MDS Treatment StrategiesПодробнее

Magrolimab + azacitidine in MDS and AMLПодробнее

Expert Video Report on Acute Myeloid Leukemia and high risk MDS from ASH 2020Подробнее

MDS transformation to AMLПодробнее

From MDS to AML: Understanding the Pathology, Diagnostics, and Genetic Relationship 10/10/17Подробнее